

ESMO Preceptorship on Lung Cancer

PROGRAMME

**ESMO
PRECEPTORSHIP**

**PARIS FRANCE
15-16 NOVEMBER 2024**

Co-Chairs

Solange Peters, Switzerland
David Planchard, France

ESMO PRECEPTORSHIP PROGRAMME

LUNG CANCER

New standards of care and future perspectives

Paris, France
15-16 November 2024

CO-CHAIRS

Solange Peters, Switzerland
David Planchard, France

SPEAKERS

Fabrice Barlesi, France
Jaafar Bennouna, France
Benjamin Besse, France
Anne-Marie Dingemans, The Netherlands
Patrick Forde, Ireland
Lizza Hendriks, The Netherlands
Keith M. Kerr, United Kingdom
Antonin Levy, France
Jordi Remon, France

LEARNING OBJECTIVES

- To learn about best clinical practice in the management of NSCLC in early, locally advanced, and metastatic stages
- To learn about the management of patients with actionable driver alterations and novel targeted agents for advanced NSCLC
- To understand the role of immune checkpoint blockade for lung cancer and to learn about novel immunotherapies
- To learn about the systemic treatment of mesothelioma, SCLC and thymoma

ACCREDITATION

The programme of this event has been accredited with **12 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4, 6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



Friday, 15 November 2024

09:00-09:10 10'	Welcome and introduction	Solange Peters, CH David Planchard, FR
09:10-11:15 125'	SESSION 1 Advances in the treatment of early stage NSCLC	Chairs: David Planchard, FR Jordi Remon, FR
30'	Introduction of immunotherapy in the perioperative setting	Patrick Forde, IE
5'	Q&A	All
25'	Targeted therapy in the perioperative setting	Jordi Remon, FR
5'	Q&A	All
25'	Immunotherapy as a component of definitive radiochemotherapy for stage III	Antonin Levy, FR
5'	Q&A	All
30'	Participants clinical case discussion (2x15')	Faculty
11:15-11:45	Coffee break	
11:45-13:45 120'	SESSION 2 Immuno-oncology treatment paradigms in advanced NSCLC	Chairs: Benjamin Besse, FR Anne-Marie Dingemans, NL
25'	State of the art for immunotherapy for non-AGA NSCLC	Lizza Hendriks, NL
5'	Q&A	All
25'	Focus on controversial subgroups for IO in non-AGA NSCLC	Solange Peters, CH
5'	Q&A	All
25'	Immunotherapy for AGA in NSCLC	Fabrice Barlesi, FR
5'	Q&A	All
30'	Participants clinical case discussion (2x15')	Faculty
13:45-14:45	Lunch	
14:45-16:25 100'	SESSION 3 Challenges and novel therapies in clinical oncology	Chairs: Solange Peters, CH Jordi Remon, FR
20'	Standard second line treatments	Anne-Marie Dingemans, NL
5'	Q&A	All
25'	Antibody–drug conjugates	David Planchard, FR
5'	Q&A	All
25'	Bispecific antibodies and new treatment strategies	Benjamin Besse, FR
5'	Q&A	All
15'	Participants clinical case discussion (1x15')	Faculty
16:25-16:55	Coffee break	
16:55-18:55 120'	SESSION 4 Hitting the target in 2024	Chairs: Lizza Hendriks, NL Solange Peters, CH
25'	Sequence for biomarker testing in advanced NSCLC (IHC, PCR, NGS and more)	Keith M. Kerr, UK

5'	Q&A	All
25'	New treatment options for EGFR-mutant NSCLC	David Planchard, FR
5'	Q&A	All
25'	Therapeutic options in uncommon EGFR-mutant or HER2-mutant NSCLC	Anne-Marie Dingemans, NL
5'	Q&A	All
30'	Participants clinical case discussion (2x15')	Faculty
20:30	Dinner	

Saturday, 16 November 2024

09:00-10:45 105'	SESSION 5 Hitting even more targets in 2024	Chairs: Fabrice Barlesi, FR Jaafar Bennouna, FR
25'	New and emerging targeted therapies in non-EGFR/HER2-mutant NSCLC	Jordi Remon, FR
5'	Q&A	All
25'	Gene fusion targets	Lizza Hendriks, NL
5'	Q&A	All
25'	ctDNA in the management of NSCLC patients	Keith M. Kerr, UK
5'	Q&A	All
15'	Participants clinical case discussion (1x15')	Faculty
10:45-11:15	Coffee break	
11:15-13:20 125'	SESSION 6 Treatment paradigms in rare situations	Chairs: Lizza Hendriks, NL David Planchard, FR
25'	The evolving treatment landscape for mesothelioma	Solange Peters, CH
5'	Q&A	All
25'	Thymic malignancies: Current and future therapeutic options	Benjamin Besse, FR
5'	Q&A	All
30'	What's next in the management of SCLC?	Jaafar Bennouna, FR
5'	Q&A	All
30'	Participants clinical case discussion (2x15')	Faculty
13:20-13:30 10'	Conclusions and farewell	Solange Peters, CH David Planchard, FR
13:30-14:30	Lunch	

Note: Each 15-min slot for clinical case discussion includes a 7' case presentation and an 8' Q&A / interactive panel discussion